Giacovazzo M, Martelletti P, Romiti A, Gallo M F, Iuvara E, Valeri M, Piazza A, Adorno D, Monaco P I, Casciani C U
Int J Clin Pharmacol Res. 1986;6(1):19-22.
The existing relationship between genetic markers of the cluster headache and the efficacy of lithium salts therapy was described in the present study. Thirty-five patients suffering from cluster headache, who were already typed for the HLA antigens, were studied. Typing was carried out with the microlymphocytotoxicity technique used by US National Institutes of Health. The patients were treated with lithium carbonate for a period of three months. Three parameters for evaluation of the efficacy of lithium therapy was used: the percentage of improvement, the wake-sleep rhythm and the pupil diameter measurement. The parameters were statistically (Student's t-test) evaluated and it was possible to separate two subgroups of patients: "responders" and "non-responders" to the lithium therapy. The phenotypical frequencies in the two subgroups was analysed using the chi 2 test, Data emerging showed a higher frequency of antigen HLA-B18 (23.8% versus 0%; p less than 0.005 pc less than 0.06) and of antigen HLA-A9 (42.9% versus 14.3%) in the "responders" subgroup. In the "non-responders" subgroup a higher frequency of antigen HLA-A1 (35.7% versus 14.3%) was found.
本研究描述了丛集性头痛的基因标记与锂盐治疗疗效之间的现有关系。对35名已经进行了HLA抗原分型的丛集性头痛患者进行了研究。分型采用美国国立卫生研究院使用的微量淋巴细胞毒性技术。患者接受碳酸锂治疗三个月。使用了三个评估锂治疗疗效的参数：改善百分比、昼夜节律和瞳孔直径测量。对这些参数进行了统计学（学生t检验）评估，并将患者分为两个亚组：对锂治疗的“反应者”和“无反应者”。使用卡方检验分析了两个亚组中的表型频率，结果显示“反应者”亚组中抗原HLA - B18（23.8%对0%；p小于0.005，pc小于0.06）和抗原HLA - A9（42.9%对14.3%）的频率较高。在“无反应者”亚组中发现抗原HLA - A1的频率较高（35.7%对14.3%）。
